Hyeran Jung

Dr. Hyeran Jung

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MKMinsoo Kim
Minsoo Kim
PKPhyu Phyu Khin
Phyu Phyu Khin
HJHyeran Jung
Hyeran Jung
CCChang Woo Chae
Chang Woo Chae
Byeong Hwa JeonByeong Hwa Jeon
Byeong Hwa Jeon
Cuk-Seong KimCuk-Seong Kim
Cuk-Seong Kim
Sepsis is a life-threatening syndrome characterized by a dysregulated host response to infection and progressive organ dysfunction. Although early antimicrobial therapy, source control, hemodynamic resuscitation, and organ support remain the foundations of care, these approaches do not directly reverse the cellular mechanisms that connect systemic inflammation to multi-organ failure. Mitochondrial dysfunction has emerged as a central mechanism linking impaired oxygen utilization, oxidative and nitrosative stress, immune-cell metabolic reprogramming, inflammatory amplification, and organ injury. During sepsis, inflammatory mediators, nitric oxide, microcirculatory abnormalities, calcium dysregulation, and metabolic stress converge on mitochondria, impairing oxidative phosphorylation and promoting mitochondrial reactive oxygen species/reactive nitrogen species (ROS/RNS) generation. When mitochondrial quality-control programs, including fission, fusion, mitophagy, and mitochondrial biogenesis, fail to restore network integrity, damaged mitochondria accumulate and become persistent sources of oxidative stress and danger signals. Mitochondrial damage-associated molecular patterns, particularly mitochondrial DNA, oxidized mitochondrial DNA, cardiolipin, ATP, and N-formyl peptides, activate innate immune pathways such as TLR9-MyD88-NF-kappaB, the NLRP3 inflammasome, and cGAS-STING signaling. In parallel, mitochondrial metabolism shapes macrophage activation, neutrophil function, T-cell competence, pyruvate-lactate handling through the pyruvate dehydrogenase complex, and the transition between hyperinflammation and immunosuppression. Clinical translation remains challenging because sepsis is biologically heterogeneous and mitochondrial dysfunction is dynamic, tissue-specific, and influenced by disease stage. This review synthesizes current knowledge on mitochondrial dysfunction in sepsis, emphasizing oxidative and nitrosative stress, mitochondrial quality control, mitochondrial damage-associated molecular pattern (DAMP) signaling, immunometabolism, organ-specific injury, candidate biomarkers, clinical translational strategies for mitochondria-targeted therapy, and future approaches based on multi-omics and artificial intelligence-assisted patient stratification. We argue that future therapeutic development should move beyond nonspecific antioxidant supplementation toward time-sensitive, phenotype-informed, and biomarker-guided mitochondrial medicine.

9 July 2026 in Medicina
Verified
Journal Article
Open access
PDF file
HJHyeran Jung
Hyeran Jung
MJMinsun Jung
Minsun Jung
Background and Objectives: Chronic kidney disease (CKD) risk classification depends on reduced estimated glomerular filtration rate (eGFR) and kidney-damage markers such as albuminuria or proteinuria. National screening statistics can identify population-level signals—referred to here as screening-based kidney risk indicators and abnormal screening prevalence—that serve as proxy indicators rather than confirmed CKD diagnoses, and require confirmatory testing when abnormal. Materials and Methods: This retrospective repeated cross-sectional ecological trend study analyzed National Health Insurance Service (NHIS) health-screening aggregate tables distributed through the Korean Statistical Information Service (KOSIS), representing individuals who underwent NHIS health screening rather than all insured individuals. Age- and region-stratified tables for eGFR, serum creatinine, urine protein, triglycerides, and hemoglobin were used. Non-eGFR indicators covered 2010–2024 and eGFR covered 2012–2024. Operational endpoints were eGFR < 60 mL/min/1.73 m2, serum creatinine ≥ 1.5 mg/dL, dipstick proteinuria ≥ 1+, triglycerides ≥ 150 mg/dL, and sex-specific anemia proxy; triglycerides and the anemia proxy were treated as associated metabolic/hematological indicators rather than kidney-specific endpoints. Crude national trends were supplemented with direct age-standardization (to the 2024 screening population) for eGFR, creatinine, proteinuria, and triglycerides, and with sex-stratified trends for all indicators. Binomial logit generalized linear models with calendar year as the predictor generated 2025–2028 forecasts; forecast reliability was assessed by temporal hold-out validation (fitting through 2020, predicting 2021–2024) and a recent-window (2018–2024) sensitivity analysis, and 95% bootstrap prediction intervals were derived by resampling model residuals and parameter uncertainty. Regional ecological correlations were assessed by Pearson and Spearman methods. Results: Dipstick proteinuria ≥ 1+ increased from 2.20% (age-standardized 2.34%) in 2012 to 3.71% in 2024 and was forecast to reach 4.64% (95% bootstrap prediction interval [PI], 4.50–4.83%) in 2028. eGFR < 60 decreased from 4.13% (age-standardized 5.20%) in 2012 to 3.43% in 2024, with a 2028 forecast of 3.06% (95% PI, 2.88–3.27%); the age-standardized decline was steeper than the crude decline, indicating the finding is not an artifact of population aging. Hold-out validation supported the eGFR, creatinine, and proteinuria forecasts (mean absolute error 0.05–0.14 percentage points) but showed poor fit for triglycerides and the anemia proxy, whose forecasts are reported as exploratory only. In 2024, eGFR < 60 reached 41.61% among persons aged ≥ 85 years. Jeonnam had the highest crude regional eGFR < 60 prevalence (5.09%), though regional comparisons could not be age-standardized. Regional eGFR < 60 was strongly correlated with elevated serum creatinine (Pearson r = 0.954, p < 0.001), reflecting their mathematical dependence rather than independent validation, and moderately correlated with the anemia proxy (Pearson r = 0.611, p = 0.009). Conclusions: NHIS/KOSIS screening data showed an age-standardization-robust upward proteinuria signal and persistent age-concentrated kidney function abnormalities. The findings support confirmatory testing after abnormal screening results and targeted kidney-risk follow-up, but they should not be interpreted as confirmed CKD incidence or prevalence.

17 July 2026 in Viruses
Verified
Journal Article
Open access
PDF file
HJHyeran Jung
Hyeran Jung
MJMinsun Jung
Minsun Jung
Background: South Korea has documented HIV cases since 1985; however, comprehensive longitudinal analyses integrating incidence, mortality, transmission dynamics, and immunological staging across the full surveillance period remain limited. This study aimed to characterize epidemiological trends from 1985 to 2024 and project future trajectories through 2028. Methods: We analyzed nationally reported aggregate HIV/AIDS surveillance data from the Korea Disease Control and Prevention Agency (KDCA) via KOSIS (1985–2024). Annual HIV incidence, AIDS case notifications, HIV-related mortality, transmission route distributions, CD4+ T-cell counts at diagnosis, and cumulative prevalent cases stratified by sex were examined. Statistical methods included simple and multiple linear regression, Pearson and Spearman correlation, hierarchical regression analysis, and time series forecasting using Holt–Winters exponential smoothing and ARIMA (AutoRegressive Integrated Moving Average) modeling. Missing data in transmission route classification (29.6% non-response in 2024) were addressed through sensitivity analysis and explicit discussion of potential misclassification bias. Results: HIV annual incidence increased significantly from one case in 1985 to a peak of 1081 in 2014 (slope = +39.25 cases/year, R2 = 0.912, p < 0.001), followed by a significant decline to 714 cases in 2024 (slope = −38.76 cases/year, R2 = 0.879, p < 0.001). A strong positive correlation was observed between HIV and AIDS incidence (Pearson r = 0.627, p = 0.017; Spearman ρ = 0.785, p < 0.001). The AIDS/HIV notification ratio declined significantly from 0.307 in 2011 to 0.196 in 2024 (slope = −0.006/year, R2 = 0.421, p = 0.012). The male-to-female notification ratio increased from 0.8:1 in 1987 to 22.0:1 in 2024 (R2 = 0.600, p < 0.001). Among reported sexual transmissions, the proportion attributable to MSM increased from 0% in 1985 to 63.7% in 2024 (slope = +1.30%/year, R2 = 0.804, p < 0.001). The proportional mortality rate declined significantly from 2.31% in 2011 to 0.93% in 2024 (slope = −0.105%/year, R2 = 0.821, p < 0.001). Time series forecasting projected continued decline to approximately 666 new HIV cases and 105 AIDS notifications annually by 2028. Conclusions: The South Korean HIV epidemic has undergone a profound epidemiological transition—from heterosexual-predominant early growth through a 2014 peak toward a declining, MSM-concentrated trajectory—with mortality progressively decoupled from incidence through expanded antiretroviral therapy coverage. Targeted MSM-focused prevention, expansion of PrEP access, and sustained ART scale-up are essential to achieving national HIV elimination targets.

24 July 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
HJHyeran Jung
Hyeran Jung
MJMinsun Jung
Minsun Jung
Background/Objectives: Korea has experienced rapid and heterogeneous shifts in cancer epidemiology since 1999. We aimed to characterize divergent incidence trajectories across the 24 major cancer types, quantify sex-specific burdens, and project case counts through 2030. Methods: Annual incidence data—including new case counts and age-standardized incidence rates (ASIRs) per 100,000 (2020 Korean standard population) stratified by sex—were extracted from the KCCR via the Korean Statistical Information Service (KOSIS) for 1999–2023. Annual percent change (APC) was estimated by log-linear regression with 95% confidence intervals (CIs). Holt–Winters damped exponential smoothing generated 2024–2030 projections with 95% prediction intervals (PIs). Changes in case ascertainment and coding over the study period were considered in interpretation. Results: Total incidence increased from 101,854 (1999) to 288,613 cases (2023), a 183.4% increase. Overall ASIR rose from 402.7 to 522.9 per 100,000. Of the 24 cancer types, 15 showed statistically significant increasing ASIR trends, 6 showed significant decreasing trends, and 3 showed no significant change. The highest-APC cancers were thyroid (+7.56%), prostate (+6.98%), testis (+5.39%), breast (+5.03%), and corpus uteri (+5.03%; all p < 0.001). The largest significant declines occurred in cervix uteri (−3.81%), larynx (−3.18%), liver (−2.90%), and stomach (−2.20%; all p < 0.001). Female ASIR increased from 294.7 to 488.9 per 100,000 (+65.9%); male ASIR increased from 573.3 to 587.0 per 100,000 (+2.4%). Total cancer incidence is projected to reach 307,091 (95% PI: 281,200–332,983) in 2026 and 330,213 (95% PI: 290,663–369,763) by 2030, with the steepest projected relative growth for prostate (+48.9%), kidney (+33.7%), and breast (+31.3%) cancers. Conclusions: Korean cancer epidemiology is undergoing a pronounced transition from infection-related toward metabolic, hormonal, and aging-related malignancies, with a marked and widening sex-specific divergence. Cancer-type-resolved projections through 2030 provide an evidence base for strategic capacity planning in Korean oncology.

Verified
Journal Article
Open access
PDF file
HJHyeran Jung
Hyeran Jung
MJMinsun Jung
Minsun Jung
Background/Objectives: Dementia poses a major public health challenge in South Korea, where population ageing has accelerated rapidly. We aimed to describe national 2016–2025 dementia prevalence trends and to generate a one-year 2026 forecast using NHIS-linked administrative data. Methods: We performed a retrospective longitudinal analysis of de-identified aggregate administrative data from the Ministry of Health and Welfare Municipal and District Dementia Status Report (2016–2025) and NHIS age–sex pivot table records. This was a purely descriptive and forecasting analysis; no inferential statistical tests were applied. Descriptive statistics were computed for national, sex-stratified, regional, and age-stratified outcomes. For the 2026 forecast, we used a prespecified demographic-offset time-series approach: the population aged 65 years or older and the estimated prevalence rate were modelled separately using damped-trend Holt exponential smoothing, then recombined to estimate patient count. Residual bootstrap resampling (20,000 iterations) was used to derive a 95% prediction interval for the patient count. A sensitivity analysis using ARIMA(1,1,0). Results: 602,633 (8.89%) in 2016 to 955,585 (9.09%) in 2025, a 58.6% increase. Females consistently showed higher prevalence than males (2025: 9.55% vs. 8.52%), and regional analysis identified South Jeolla Province (10.17%) as the highest-prevalence region and Ulsan Metropolitan City (8.10%) as the lowest. The female-to-male cumulative rate ratio reached 2.49 in the ≥85-year group. The primary 2026 forecast estimated 1,003,407 dementia patients among adults aged 65 years or older, with an estimated prevalence of 9.19% and a 95% prediction interval of 983,838–1,022,158. Conclusions: South Korea’s rising dementia burden is primarily driven by population ageing rather than a sharp increase in age-specific prevalence. The 2026 forecast supports urgent planning for a national dementia care population of approximately one million people.

20 July 2026 in Cancers
Verified
Journal Article
Open access
PDF file
HJHyeran Jung
Hyeran Jung
MJMinsun Jung
Minsun Jung
Background/Objectives: Korea has undergone rapid epidemiological transitions in cancer incidence over the past two decades. Using a 25-year nationwide dataset (1999–2023), we characterize long-term trends for 61 cancer types, examine inter-cancer correlations, and forecast incidence to 2028. Methods: Annual incidence counts, crude rates, and age-standardized incidence rates (ASIRs) stratified by sex were obtained from the Korea Central Cancer Registry (KCCR) via the Korean Statistical Information Service (KOSIS). Annual percent change (APC) was estimated using log-linear regression. Pearson correlation coefficients were computed among cancer-specific ASIRs, with false-discovery-rate (FDR) correction for multiple comparisons. Multiple and hierarchical regression evaluated the statistical association of individual cancer types with the overall cancer rate, and variance inflation factors (VIFs) were used to quantify multicollinearity. Time series forecasting used damped Holt–Winters exponential smoothing; forecast accuracy was assessed with rolling-origin cross-validation (RMSE, MAE, MAPE) and benchmarked against ARIMA. A sensitivity analysis excluding the pandemic years (2020–2021) tested the robustness of trend estimates. Five-year prevalence data (2007–2023) were analyzed from the KCCR prevalence module. Results: Total cancer incidence increased from 101,854 in 1999 to 288,613 in 2023, a 183% increase. The overall ASIR rose from 402.7 to 522.9 per 100,000 (2020 standard population). The three fastest-growing cancers were thyroid (APC +7.56%, p < 0.001), prostate (+6.98%, p < 0.001), and breast (+5.03%, p < 0.001). Stomach (APC −2.20%) and liver (−2.90%) cancers showed significant declines. Hierarchical regression showed that adding thyroid, breast, and prostate to lung and stomach increased explained variance from R2 = 0.449 to 0.997; however, high VIF values (up to ~263) indicate substantial multicollinearity and compositional dependence, so these coefficients should not be read as independent causal contributions. Holt–Winters and ARIMA produced comparable accuracy (mean MAPE 4.6% vs. 4.7%). The five-year cancer prevalence pool reached 1,035,107 in 2023. Forecasting projects a total incidence of approximately 319,000 by 2028. Conclusions: Korean cancer epidemiology is undergoing a transition from infection-related cancers toward hormone-sensitive and screening-detectable malignancies. These findings support strategic resource allocation for high-growth cancers while maintaining vigilance over rising pancreatic and other emerging cancers.